PDX-derived organoids combine the genetic fidelity of patient tumors with the scalability and speed of in vitro platforms—delivering a powerful model for evaluating therapeutic response.

These models enable:
🔷 More accurate efficacy prediction
🔷 Reduced translational gaps
🔷 Faster iteration for lead optimization

This approach strengthens the bridge between preclinical data and clinical outcomes—empowering oncology researchers to make more confident decisions in early drug development.